🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Navidea inks LOI for out-licensing of NAV4694; shares ahead 37%

Published 10/27/2017, 10:38 AM
© Reuters.  Navidea inks LOI for out-licensing of NAV4694; shares ahead 37%
NAVB
-
  • Thinly traded nano cap Navidea Biopharmaceuticals (NAVB +37.3%) is up on almost a 20x surge in volume in response to its announcement that it has executed a non-binding letter of intent (LOI) with Cerveau Technologies sublicensing global rights to conduct research using beta-amyloid imaging agent NAV4694 in early-onset Alzheimer's disease in addition to an exclusive license to develop and commercialize NAV4694 in China, Australia, Singapore and Canada.
  • If the companies ink a definitive agreement, the litigation initiated by Beijing-based Sinotau Pharmaceutical Group against Navidea will be dismissed since Cerveau is a JV between Sinotau and Toronto-based Enigma Biomedical Group. Sinotau sued Navidea in 2015 accusing it of backing out of a global deal to develop NAV4694.
  • Now read: Integer Holdings Corporation 2017 Q3 - Results - Earnings Call Slides


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.